Cytostatic cancer therapy modulates monocyte-macrophage cell functions: how it impacts on treatment outcomes
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-41-no-3.13597Keywords:
cytostatic therapy, immunomodulation, monocytes, tumor progression, tumor-associated macrophagesAbstract
Summary. Macrophages are important effectors of innate immunity and the key component of the tumor microenvironment strongly influencing cancer disease outcome and efficiency of cancer therapy. Moreover, recent data have shown that monocytes as macrophage precursors can impact on tumor ability to progression. It’s well known that although tumor-associated macrophages consist of diverse populations, in general, they have tumor-supporting activity. To change tumor-supporting state of tumor-associated macrophages toward tumor-inhibiting mode is one of prospective aims of modern cancer immunotherapy. Cytostatics seems to be possible tools to achieve this aim, because recently it has been shown that chemo- and radiotherapy possess immunomodulatory effects. Most of the findings are related to lymphocytes — T-lymphocytes and NK-cells, but not to monocyte/macrophage lineage. In the review, we have analyzed how cytostatic drugs influence the properties of monocyte/macrophage lineage cells to prospect using of chemotherapy to enhance their antitumor activity.
References
Ricci MS. Chemotherapeutic approaches for targeting cell death pathways. Oncologist 2006; 11: 342–57.
Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011; 8: 151–60.
Coffelt SB, de Visser KE. Immune-mediated mechanisms influencing the efficacy of anticancer therapies. Trends Immunol 2015; 36: 198–216.
Laoui D, Van Overmeire E, Van Ginderachter JA. Unsuspected allies: Chemotherapy teams up with immunity to fight cancer. Eur J Immunol 2013; 43: 2538–42.
Kroemer G, Galluzzi L, Zitvogel L. Immunological effects of chemotherapy in spontaneous breast cancers. Oncoimmunology 2013; 2: 41–4.
Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005; 5: 953–64.
Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature 2013; 496: 445–55.
Cherdyntseva NV, Mitrofanova IV, Buldakov MA, et al. Macrophages and tumor progression: on the way to macrophage-specific therapy. Bull Sib Med 2017; 16: 61–74.
Ngambenjawong C, Gustafson HH, Pun SH, et al. Progress in tumor-associated macrophage (TAM)-targeted therapeutics. Adv Drug Deliv Rev 2017; 114: 206–21.
Ponzoni M, Pastorino F, Di Paolo D, et al. Targeting macrophages as a potential therapeutic intervention: Impact on inflammatory diseases and cancer. Int J Mol Sci 2018; 19: 1953.
Bercovici N, Guérin MV, Trautmann A, et al. The Remarkable Plasticity of Macrophages: A Chance to Fight Cancer. Front Immunol 2019; 10: 1–9.
Röszer T. Understanding the biology of self-renewing macrophages. Cells 2018; 7: 103.
Ginhoux F, Jung S. Monocytes and macrophages: Developmental pathways and tissue homeostasis. Nat Rev Immunol 2014; 14: 392–404.
Varol C, Mildner A, Jung S. Macrophages: development and tissue specialization. Annu Rev Immunol 2015; 33: 643–75.
Laurenti E, Göttgens B. From haematopoietic stem cells to complex differentiation landscapes. Nature 2016; 25: 289–313.
Paul F, Arkin Y, Giladi A, et al. Transcriptional heterogeneity and lineage commitment in myeloid progenitors. Cell 2015; 163: 1663–77.
Movahedi K, Laoui D, Gysemans C, et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res 2010; 70: 5728–39.
Cortez-Retamozo V, Etzrodt M, Newton A, et al. Origins of tumor-associated macrophages and neutrophils. Proc Natl Acad Sci 2012; 109: 2491–6.
Sawanobori Y, Ueha S, Kurachi M, et al. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 2008; 111: 5457–66.
Yoshimura T. The chemokine MCP-1 (CCL2) in the host interaction with cancer: A foe or ally? Cell Mol Immunol 2018; 15: 335–45.
Franklin RA, Liao W, Sarkar A, et al. The cellular and molecular origin of tumor-associated macrophages. Science 2014; 344: 921–5.
Pucci F, Garris C, Lai CP, et al. SCS macrophages suppress melanoma by restricting. Science 2016; 352: 242–6.
Yang X, Wang X, Liu D, et al. Epigenetic regulation of macrophage polarization by DNA methyltransferase 3b. Mol Endocrinol 2014; 28: 565–74.
Cheng C, Huang C, Ma TT, et al. SOCS1 hypermethylation mediated by DNMT1 is associated with lipopolysaccharide-induced inflammatory cytokines in macrophages. Toxicol Lett 2014; 225: 488–97.
Zhang Q, Zhao K, Shen Q, et al. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature 2015; 525: 389–93.
Stender JD, Pascual G, Liu W, et al. Control of proinflammatory gene programs by regulated trimethylation and demethylation of histone H4K20. Mol Cell 2012; 48: 28–38.
Schliehe C, Flynn EK, Vilagos B, et al. The methyltransferase Setdb2 mediates virus-induced susceptibility to bacterial superinfection. Nat Immunol 2015; 16: 67–74.
Fan Z, Li J, Li P, et al. Protein arginine methyltransferase 1 (PRMT1) represses MHC II transcription in macrophages by methylating CIITA. Sci Rep 2017; 7: 1–9.
Kittan NA, Allen RM, Dhaliwal A, et al. Cytokine induced phenotypic and epigenetic signatures are key to establishing specific macrophage phenotypes. PLoS One 2013; 8: 1–15.
Nguyen KD. Circadian gene Bmal1 regulates diurnal oscillations of Ly6C. Science 2013; 341: 1483–8.
Liu Y, Zhang Q, Ding Y, et al. Histone lysine methyltransferase Ezh1 promotes TLR-triggered inflammatory cytokine production by suppressing Tollip. J Immunol 2015; 194: 2838–46.
Xia M, Liu J, Wu X, et al. Histone methyltransferase ash1l suppresses interleukin-6 production and inflammatory autoimmune diseases by inducing the ubiquitin-editing enzyme A20. Immunity 2013; 39: 470–81.
van Essen D, Zhu Y, Saccani S. A feed-forward circuit controlling inducible NF-κB target gene activation by promoter histone demethylation. Mol Cell 2010; 39: 750–60.
Zhu Y, van Essen D, Saccani S. Cell-type-specific control of enhancer activity by H3K9 trimethylation. Mol Cell 2012; 46: 408–23.
Foster SL, Hargreaves DC, Medzhitov R. Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 2007; 447: 972–8.
Satoh T, Takeuchi O, Vandenbon A, et al. The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nat Immunol 2010; 11: 936–44.
Mounce BC, Mboko WP, Kanack AJ, et al. Primary macrophages rely on histone deacetylase 1 and 2 expression to induce type i interferon in response to gammaherpesvirus infection. J Virol 2014; 88: 2268–78.
Chen X, Barozzi I, Termanini A, et al. Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophages. Proc Natl Acad Sci 2012; 109: E2865–74.
Mullican SE, Gaddis CA, Alenghat T, et al. Histone deacetylase 3 is an epigenomic brake in macrophage alternative activation. Genes Dev 2011; 25: 2480–8.
Yang Q, Wei J, Zhong L, et al. Cross talk between histone deacetylase 4 and stat6 in the transcriptional regulation of arginase 1 during mouse dendritic cell differentiation. Mol Cell Biol 2015; 35: 63–75.
Kapellos TS, Iqbal AJ. Epigenetic control of macrophage polarisation and soluble mediator gene expression during inflammation. Mediators Inflamm 2016; 2016: 6591703.
Nicodeme E, Jeffrey KL, Schaefer U, et al. Suppression of inflammation by a synthetic histone mimic. Nature 2010; 468: 1119–23.
Guerriero JL, Sotayo A, Ponichtera HE, et al. Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages. Nature 2017; 543: 428–32.
Lobera M, Madauss KP, Pohlhaus DT, et al. Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. Nat Chem Biol 2013; 9: 319–25.
Reichman H, Munitz A. Harnessing class II histone deacetylases in macrophages to combat breast cancer. Cell Mol Immunol 2017; 14: 575–7.
Cassetta L, Pollard JW. Repolarizing macrophages improves breast cancer therapy. Cell Res 2017; 27: 963–4.
Sainz B, Carron E, Vallespinós M, et al. Cancer stem cells and macrophages: implications in tumor biology and therapeutic strategies. Mediators Inflamm 2016; 2016: 9012369.
Yang M, McKay D, Pollard JW, et al. Diverse functions of macrophages in different tumor microenvironments. Cancer Res 2018; 78: 5492–503.
Gwak JM, Jang MH, Kim D Il, et al. Prognostic value of tumor-associated macrophages according to histologic locations and hormone receptor status in breast cancer. PLoS One 2015; 10: e0125728.
Buldakov M, Zavyalova M, Krakhmal N, et al. CD68+, but not stabilin-1+ tumor associated macrophages in gaps of ductal tumor structures negatively correlate with the lymphatic metastasis in human breast cancer. Immunobiology 2017; 222: 31–8.
Mantovani A, Schioppa T, Porta C, et al. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 2006; 25: 315–322.
Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 2012; 122: 787–95.
Larionova I, Cherdyntseva N, Liu T, et al. Interaction of tumor-associated macrophages and cancer chemotherapy. Oncoimmunology 2019; 8: 1–15.
Nazir T, Taha N, Islam A, et al. Monocytopenia; induction by vinorelbine, cisplatin and doxorubicin in breast, non-small cell lung and cervix cancer patients. Int J Health Sci (Qassim) 2016; 10: 542–7.
Saeed L, Patnaik MM, Begna KH, et al. Prognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: A single center experience in 889 patients. Blood Cancer J 2017; 7: e550–6.
Ouyang W, Liu Y, Deng D, et al. The change in peripheral blood monocyte count: A predictor to make the management of chemotherapy-induced neutropenia. J Cancer Res Ther 2018; 14: 565.
Nakasone ES, Askautrud HA, Kees T, et al. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell 2012; 21: 488–503.
de Nardo DG, Brennan DJ, Rexhepaj E, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011; 1: 54–67.
Shree T, Olson OC, Elie BT, et al. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev 2011; 25: 2465–79.
Kioi M, Vogel H, Schultz G, et al. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 2010; 120: 694–705.
Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity 2019; 51: 27–41.
Hughes R, Qian BZ, Rowan C, et al. Perivascular M2 macrophages stimulate tumor relapse after chemotherapy. Cancer Res 2015; 75: 3479–91.
Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Mol Psychiatry 2015; 20: 1588–95.
de Palma M, Lewis CE. Macrophages limit chemotherapy. Cancer Discov 2011; 1: 54–67.
Hu J, Kinn J, Zirakzadeh AA, et al. The effects of chemotherapeutic drugs on human monocyte-derived dendritic cell differentiation and antigen presentation. Clin Exp Immunol 2013; 172: 490–9.
Loberg RD, Ying C, Craig M, et al. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res 2007; 67: 9417–24.
Bonapace L, Coissieux MM, Wyckoff J, et al. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature 2014; 515: 130–3.
Patysheva MR, Stakheeva MN, Larionova IV, et al. Monocytes and cancer: promising role as a diagnostic marker and application in therapy. Bull Sib Med 2019; 18: 60–75.
Hughes R, Qian BZ, Rowan C, et al. Perivascular M2 macrophages stimulate tumor relapse after chemotherapy. Cancer Res 2015; 75: 3479–91.
Baghdadi M, Wada H, Nakanishi S, et al. Chemotherapy-induced IL34 enhances immunosuppression by tumor-associated macrophages and mediates survival of chemoresistant lung cancer cells. Cancer Res 2016; 76: 6030–42.
Iida N, Dzutsev A, Stewart CA, et al. Commensal bacteria control cancer the tumor microenvironment. Science 2013; 342: 967–71.
Singh RAK, Sodhi A. Antigen presentation by cisplatin-activated macrophages: Role of soluble factor(s) and second messengers. Immunol Cell Biol 1998; 76: 513–9.
Wanderley CW, Colón DF, Luiz JPM, et al. Paclitaxel reduces tumor growth by reprogramming tumor-associated macrophages to an M1 profile in a TLR4-dependent manner. Cancer Res 2018; 78: 5891–900.
Kodumudi KN, Woan K, Gilvary DL, et al. A novel chemoimmunomodulating property of docetaxel: Suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res 2010; 16: 4583–94.
Buhtoiarov IN, Sondel PM, Wigginton JM, et al. Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages. Immunology 2011; 132: 226–39.
Tran K, Risingsong R, Royce DB, et al. The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer. Carcinogenesis 2013; 34: 199–210.
Sugimura K, Miyata H, Tanaka K, et al. High infiltration of tumor-associated macrophages is associated with a poor response to chemotherapy and poor prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer. J Surg Oncol 2015; 111: 752–9.
Wang B, Xu D, Yu X, et al. Association of intra-tumoral infiltrating macrophages and regulatory T cells is an independent prognostic factor in gastric cancer after radical resection. Ann Surg Oncol 2011; 18: 2585–93.
Malesci A, Bianchi P, Celesti G, et al. Tumor-associated macrophages and response to 5-fluorouracil adjuvant therapy in stage III colorectal cancer. Oncoimmunology 2017; 6: 1–11.
Di Caro G, Cortese N, Castino GF, et al. Dual prognostic significance of tumour-Associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy. Gut 2015; 65: 1710–20.
Litviakov N, Tsyganov M, Larionova I, et al. Expression of M2 macrophage markers YKL-39 and CCL18 in breast cancer is associated with the effect of neoadjuvant chemotherapy. Cancer Chemother Pharmacol 2018; 82: 99–109.
Hannesdóttir L, Tymoszuk P, Parajuli N, et al. Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response. Eur J Immunol 2013; 43: 2718–29.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
